Showing 2671-2680 of 4063 results for "".
- Second Sight Receives FDA Approval for the Argus 2s Retinal Prosthesis Systemhttps://modernod.com/news/second-sight-receives-fda-approval-for-the-argus-2s-retinal-prosthesis-system/2478941/Second Sight Medical Products announced FDA has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). Th
- Ocuphire Announces Publication of MIRA-1 Phase 2b Results Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxolhttps://modernod.com/news/ocuphire-announces-publication-of-mira-1-phase-2b-results-demonstrating-reduction-of-pharmacologically-induced-mydriasis-by-nyxol/2478940/Ocuphire Pharma announced that the results from the MIRA-1 (NCT04024891) phase 2b clinical trial evaluating the safety and efficacy of Nyxol in the reversal of mydriasis have been published in Optometry and Visual Science. The article will appear in the print edition and is available on-
- Clearside Biomedical Completes Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-patient-dosing-in-first-cohort-of-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478927/Clearside Biomedical announced completion of dosing in the first cohort of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicenter,
- SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Advance Gene Therapieshttps://modernod.com/news/saliogen-therapeutics-announces-closing-of-20-million-series-a-financing-to-advance-gene-therapies/2478925/SalioGen Therapeutics announced that it has closed a $20 million Series A financing to support the preclinical validation of the company’s proprietary Exact DNA Integration Technology (EDIT) platform for the development of durable, safe and affordable in vivo gene the
- Retinal Therapeutics Development Company Oxular Completes $37 Million (£27 million) Financinghttps://modernod.com/news/retinal-therapeutics-development-company-oxular-completes-37-million-27-million-financing/2478922/Oxular announced that it has completed a $37 million (£27 million) to fund planned further clinical development of its lead asset, OXU-001, for the treatment of diabetic macular edema (DME), as well as accelerating development of its early-product pipeline. The financing was led by Forbion
- The Vision Council Releases Results of January 2021 Eyecare Provider Insights Surveyhttps://modernod.com/news/the-vision-council-releases-results-of-january-2021-eyecare-provider-insights-survey/2478890/The Vision Council has released the results of the January 2021 Eyecare Provider Insights Survey. The Vision Council fielded the survey to the organization’s panel of more than 1,700 eyecare providers during the last week of January. The survey, which will be conducted on an ongoing basis to trac
- Analysis: Roughly 2,000 Hospitals Fully Compliant With New Price Transparency Rulehttps://modernod.com/news/analysis-roughly-2000-hospitals-fully-compliant-with-new-price-transparency-rule/2478879/A new analysis found that roughly 2,000 hospitals out of more than 6,000 reviewed were highly transparent posting their payer-negotiated rates per a new federal rule, according to a FierceHealthcare
- Regenxbio Announces Additional Positive Interim Phase 1/2a and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-and-long-term-follow-up-data-of-rgx-314-for-the-treatment-of-wet-amd/2478873/Regenxbio reported additional positive interim data from Cohorts 4 and 5 of its RGX-314 phase 1/2a trial for the treatment of wet age-related macular degeneration (AMD), and Cohort 3 of its Long-Term Follow-Up (LTFU) study. RGX-314 is a potential best-in-class, one-time gene therapy for the treat
- Clearside Biomedical Announces CLS-AX Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Programhttps://modernod.com/news/clearside-biomedical-announces-cls-ax-presentation-delivered-at-angiogenesis-exudation-and-degeneration-2021-program/2478874/Clearside Biomedical announced that David M. Brown, MD, delivered a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD” at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Ba
- GenSight Biologics Announces Publication of Results from Lumevoq Phase 1/2a Clinical Trial REVEAL in BioDrugshttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-phase-1-2a-clinical-trial-reveal-in-biodrugs/2478868/GenSight Biologics announced that the journal BioDrugs has published results from REVEAL, the phase 1/2a clinical trial that evaluated the safety of Lumevoq gene therapy in subjects with ND4 Leber Hereditary Optic Neuropathy (LHON) and determined the dose subsequently used in the ph